Press Releases

Date Title and Summary
Toggle Summary G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Garry Nicholson has been appointed to its board of directors, effective September 12, 2018 . “We are pleased to welcome Garry as an
Toggle Summary G1 Therapeutics Announces Appointment of New Members to the Board of Directors
RESEARCH TRIANGLE PARK, N.C. , June 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have been appointed to its board of directors, effective June 7, 2018 .
Toggle Summary G1 Therapeutics Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock at a public offering price of $29.50 , including 510,000
Toggle Summary G1 Therapeutics Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $60.00 per share, including
Toggle Summary G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
RESEARCH TRIANGLE PARK, N.C. , April 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso ® (osimertinib) in
Toggle Summary G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L SCLC) Statistically significant improvements in both primary endpoints of occurrence of Grade 4 neutropenia and duration of
Toggle Summary G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
Statistically significant results highlight benefit of trilaciclib in several prospectively-defined parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia,
Toggle Summary G1 Therapeutics Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $60.00 per share, for total
Toggle Summary G1 Therapeutics Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50 , for total gross
Toggle Summary G1 Therapeutics Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Toggle Summary G1 Therapeutics Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Toggle Summary G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
RESEARCH TRIANGLE PARK, N.C. , July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth.
Toggle Summary G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy Data presented at the European Society for Medical Oncology ( ESMO ) 2018 Congress RESEARCH TRIANGLE PARK, N.C. , Oct. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) showed promising safety,
Toggle Summary G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update
U.S. and European regulatory meetings scheduled based on positive trilaciclib Phase 2a myelopreservation data Preliminary data from G1T38 Phase 1b trial in breast cancer to be presented at ASCO on June 2 Management to host webcast and conference call today at 4:30 p.m.
Toggle Summary G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October   Initiated Phase 2a enrollment of lerociclib (G1T38) in ER+, HER2- breast cancer; positive Phase 1b data presented at ASCO 2018   Management to host
Toggle Summary G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
Topline data expected in March 2018 from first of three ongoing Phase 2 trials evaluating the myelopreservation benefits of trilaciclib Management to host webcast and conference call today at 4:30 p.m. EST RESEARCH TRIANGLE PARK, N.C. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib Preliminary data from three additional randomized Phase 2 clinical trials of trilaciclib expected by
Toggle Summary G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
New data analyses demonstrate multi-lineage benefits of trilaciclib on neutrophils, red blood cells and lymphocytes in treatment of first-line small cell lung cancer RESEARCH TRIANGLE PARK, N.C. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference .
Toggle Summary G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips , Chief Financial Officer and Senior Vice President, Corporate Development will present a company overview at the following
Toggle Summary G1 Therapeutics to Present at Investor Conferences in March 2018
RESEARCH TRIANGLE PARK, N.C. , March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following upcoming investor conferences in March:
Toggle Summary G1 Therapeutics to Present at Investor Conferences in November 2018
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in
Toggle Summary G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018
RESEARCH TRIANGLE PARK, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following investor conference: UBS Global
Toggle Summary G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will present a company overview at the following investor conference: Wedbush PacGrow Healthcare
Toggle Summary G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) will be presented in a poster
Toggle Summary G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , April 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preclinical data on both of the company’s CDK4/6 inhibitors will be presented at the 2018 American Association for Cancer Research Annual
Toggle Summary G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic
Toggle Summary G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018
RESEARCH TRIANGLE PARK, N.C. , April 26, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2018 on Thursday, May 3 at 4:30
Toggle Summary G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2018 on Wednesday, August
Toggle Summary G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2018 on Wednesday, November
Toggle Summary G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018
RESEARCH TRIANGLE PARK, N.C. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that fourth quarter and full-year 2017 financial results will be reported on Wednesday, February 21, 2018 , after the close of U.S.
Toggle Summary G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018
Management to host webcast and conference call today at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its
Toggle Summary Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile consistent with previously reported trials; no trilaciclib-related serious adverse